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Abstract Recent developments in the field of targeted
therapy have led to the discovery of a new drug, plerixafor,
that is a specific inhibitor of the CXCR4 receptor.
Plerixafor acts in concert with granulocyte colony-
stimulating factor (G-CSF) to increase the number of stem
cells circulating in the peripheral blood (PB). Therefore, it
has been applied in the field of hematopoietic stem cell
mobilization. We analyzed retrospectively data regarding
stem cell mobilization with plerixafor in a cohort of 61
patients suffering from multiple myeloma (N=23), non-
Hodgkin’s lymphoma (N=20), or Hodgkin’s lymphoma
(N=18). At least one previous mobilization attempt had
failed in 83.6% of these patients, whereas 16.4% were
predicted to be poor mobilizers. The median number of
CD34+ cells in the PB after the first administration of
plerixafor was 22/μL (range of 0–121). In total, 85.2% of
the patients proceeded to cell collection, and a median of
two (range of 0–4) aphereses were performed. A minimum
of 2.0×10
6 CD34+ cells per kilogram of the patient’s body
weight (cells/kg b.w.) was collected from 65.6% of patients,
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DOI 10.1007/s00277-010-1098-7and the median number of cells collected was 2.67×10
6
CD34+ cells/kg b.w. (0–8.0). Of the patients, 55.7% had
already undergone autologous stem cell transplantation, and
the median time to neutrophil and platelet reconstitution
was 12 and 14 days, respectively. Cases of late graft failure
were not observed. We identified the diagnosis of non-
Hodgkin’s lymphoma and previous radiotherapy as inde-
pendent factors that contributed to failure of mobilization.
The current report demonstrates the satisfactory efficacy of
plerixafor plus G-CSF for stem cell mobilization in heavily
pre-treated poor or predicted poor mobilizers.
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Introduction
Autologous stem cell transplantation (autoSCT) is a widely
established treatment option in patients suffering from
multiple myeloma (MM) or lymphomas [1, 2]. In MM,
despite the development of new drug therapies, autoSCT
still remains the gold standard treatment in those patients
who qualify on the basis of their age and general condition.
In MM, autoSCT is aimed at achieving remission or
extending the remission period. In non-Hodgkin’sl y m p h o m a
(NHL) and Hodgkin’s lymphoma (HL), autoSCT is reserved
especially for patients with aggressive disease with a poor
prognosis, or those who have relapsed after remission had
been achieved previously. In contrast to MM, cure of the
disease is the main aim of autoSCT in lymphoma.
AutoSCT involves high-dose myeloablative chemother-
apy, which is supposed to eradicate the tumor, followed by
an infusion of autologous hematopoietic stem cells (HSCs)
to rescue hematopoiesis in the patient. Nowadays, autolo-
gous HSCs are usually isolated from the peripheral blood
(PB) of patients, instead of being aspirated from the bone
marrow (BM) [3]. However, although HSCs circulate in the
PB under physiological conditions, in order to collect a
dose of cells that is sufficient for the renewal of
hematopoiesis, they need to be mobilized from the BM.
According to the literature and common practice, a
minimum dose of ≥2.0×10
6 CD34+ cells per kilogram of
the patient’s body weight (cells/kg b.w.) is required for
transplantation [4, 5]. The approaches that are used
commonly to mobilize stem cells include the application
of granulocyte colony-stimulating factor (G-CSF) either
alone or in combination with chemotherapy. The G-CSF is
thought to stimulate the production of BM neutrophils,
which secrete proteolytic enzymes that cleave the adhesion
molecules that attach HSCs to the stroma of the BM [6]. In
this way, HSCs are released into the circulation. Stroma-
derived factor-1 (SDF-1) is probably the key molecule that
is cleaved. SDF-1 is produced by BM stromal cells and is
found within the BM as both a protein attached to the cell
membrane and a soluble factor [7]. The SDF-1 receptor,
CXCR4, is expressed differentially at the surface of
multiple types of blood cells, which include neutrophils
and stem cells/progenitors. SDF-1 acts chemotactically on
these cells to attract them to the BM and to prevent them
leaving the BM niche. Unfortunately, a proportion of
patients fail to release sufficient CD34+ cells after the
mobilization procedure, which results in a lack of material
for autoSCT. The failure rate of primary mobilization was
reported to be as high as 5% in MM and up to 35% in
lymphomas [6, 8]. The failure rate of re-mobilization seems
to be even higher [9].
On the basis of recent reports, it seems that inhibition of
the CXCR4 receptor might provide an important adjunct to
the multispectral action of G-CSF. A specific inhibitor of
CXCR4, plerixafor (AMD3100, Mozobil), has been shown
to act in synergy with G-CSF to improve its mobilizing
capacity significantly [10, 11]. Moreover, it has been shown
to have a good safety profile, with side effects that are
limited in general to a low degree of nausea, diarrhea, or
skin reactions at the injection site, if any. Before the drug
was made available commercially, it was provided to
American and European transplant centers free of charge,
within the Compassionate Use Program (CUP). The current
report summarizes the outcome of HSC mobilizations based
on the use of plerixafor that were carried out within the
CUP in 61 patients in Poland.
Patients and methods
Study design
The study has been performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki. The approval by the ethics committee was not
required, as plerixafor was used according to registration
guidelines. All patients gave their informed consent prior to
their inclusion in the study. The recommended protocol for
mobilization included a daily injection of G-CSF (10 μg/kg)
administered subcutaneously (s.c.) each morning for four
consecutive days before the administration of plerixafor;
however, clinicians were permitted to administer G-CSF
according to the local practice guidelines. On the evening of
the fourth day, at approximately 10 p.m., patients received an
injection of plerixafor (240 μg/kg s.c.). The following
morning, it was recommended that the patients received their
doseofG-CSF atleast 1h beforeapheresis,after which HSCs
were isolated. This procedure was then repeated, for up to
3 days of administration of plerixafor in total, to give a
maximum of seven injections of G-CSF and three aphereses.
558 Ann Hematol (2011) 90:557–568The investigators could decide to discontinue the
mobilization procedure if the patient failed to release a
satisfactory number of CD34+ cells into the PB or they
failed to collect enough cells to warrant continuation.
Alternatively, the mobilization procedure could be stopped
earlier if the required number of CD34+ cells has been
collected. Counts of nucleated cells (NCs) and CD34+ cells
in PB and in apheresis products were evaluated at local
laboratories. The aphereses and cell processing followed
local standard operating procedures that had been elaborated
in each center. The timing and protocol of autoSCT were
also based on individual clinical decisions. If insufficient
cells were collected following mobilization with plerixafor
and G-CSF, cells could be pooled for transplantation with
those collected at other times. The recovery of neutrophils
and platelets was measured in accordance with site
practices, and patients were monitored for graft durability
and disease status in a routine fashion. The criteria used to
evaluate efficacy were the PB CD34+ cell count, apheresis
yield, engraftment of neutrophils and platelets, and graft
durability.
Inclusion and exclusion criteria
Physicians were requested to complete regulatory docu-
ments, which included informed consent forms, and to
agree to follow the protocol provided by the manufacturer
of plerixafor. Patients had to meet the following criteria to
receive plerixafor: (1) aged 18 to 78 years with a diagnosis
of HL, NHL, or MM; (2) eligible to undergo autoSCT
transplantation; (3) previous conventional therapies for
HSC collection had failed, or on the basis of a low PB
CD34+ cell count following conventional mobilization
therapy, the physician did not think there was a reasonable
chance of collecting enough cells; (4) adequate cardiac,
renal, and pulmonary function sufficient to undergo
apheresis and transplantation, i.e., eligible by institutional
standards for autoSCT; (5) WHO performance status of 0 or
1; (6) white blood cell (WBC) count >2.5 G/L and absolute
neutrophil count >1.5 G/L; (7) platelet (Plt) count >85 G/L;
serum creatinine ≤1.5 mg/dL; (8) serum aspartate amino-
transferase/serum glutamic oxaloacetic transaminase, serum
alanine aminotransferase (ALT)/serum glutamic pyruvic
transaminase, and total bilirubin below the two-fold upper
limit of normal; (9) no active infection with hepatitis B or
C; (10) signed informed consent; and (11) agreed to use an
approved form of contraception, when needed.
The exclusion criteria were (1) a diagnosis of any acute
or chronic leukemia (including plasma cell leukemia) or
myelodysplastic syndrome (for patients with MM, a PB
smear was evaluated within 24 h before the first dose of
plerixafor; patients who showed the presence of plasma
cells or blasts that indicated plasma cell leukemia should
have been excluded from receiving plerixafor; (2) a co-
morbid condition that, in the view of the treating physician,
rendered the patient at high risk from treatment complica-
tions; (3) vasculitis or autoimmune disease; (4) brain
metastases, carcinomatous meningitis, or any other malig-
nancy, unless the patient had been free of disease for at least
5 years following therapy with curative intent; (5) clinically
significant heart disease, e.g., as indicated by results of an
electrocardiography or other study (exercise study, scan)
that were suggestive of previously undiagnosed cardiac
ischemia, or a history of clinically significant rhythm
disturbance (arrhythmia) or other conduction abnormality
in the last year; (6) acute infection and/or fever (body
temperature >38°C); (7) hypercalcemia (>1 mg/dL above
the upper limit of normal); (8) pregnancy or breastfeeding
among women; (9) lack of willingness among patients
(male and female) with child-bearing potential to imple-
ment adequate birth control; (10) known HIV infection;
(11) obesity exceeding 175% of ideal body weight; and
(12) receipt of experimental treatment during mobilization.
Definitions
A chemotherapy regimen was defined as one or more
courses of chemotherapy of a certain type, including
conditioning regimens and chemotherapy used for previous
and current stem cell mobilization. The number of
chemotherapy courses was recorded accordingly. The status
of kidney, heart, or liver insufficiency was based on
individual assessment by the investigators. Proven poor
mobilizers were defined as patients in whom at least one
previous mobilization attempt had failed. Predicted poor
mobilizers were defined as patients who did not release a
satisfactory minimum number of CD34+ cells into the PB
during the current mobilization or from whom too few
CD34+ cells were collected during the initial apheresis to
warrant successful continuation. The disease status at the
time of mobilization was described as complete remission
(CR), partial remission (PR), stable disease (StD), or
progressive disease (PD) and was defined according to
commonly accepted criteria [12, 13]. The satisfactory
number of PB CD34+ cells to allow stem cell collection
was defined as 20 CD34+ cells/μL. Successful mobilization
was defined as the collection of a total of ≥2.0×10
6 CD34+
cells/kg b.w. The day of neutrophil recovery was defined as
the first of 2 days with a neutrophil count ≥0.5 G/L. The
day of platelet recovery was defined as the first of 2 days
with a Plt count ≥20 G/L, in the absence of transfusion.
Data audit
All Polish transplant centers were invited to participate in
the retrospective study. A letter of invitation was sent on
Ann Hematol (2011) 90:557–568 559January 15, 2010 asking whether the center had ever used
plerixafor under the CUP to mobilize stem cells in patients.
They were requested to report the total number of patients
who had undergone the mobilization procedure, regardless
of whether or not they participated in the study and
regardless of the success or failure of the outcome. A
response was obtained from all the centers, and all of them
agreed to submit data regarding all the patients who had
undergone the mobilization procedure with plerixafor,
without exception. They then received detailed question-
naires and submitted data before February 15, 2010. The
follow-up questionnaire was sent on April 1, 2010 and
received back before April 30, 2010.
Statistical methods
Categorical data were summarized as the numbers and
percentage of patients who fell into each category. The
differences between categorical variables were calculated
with the χ
2 test. Non-categorical data were reported as the
median and range as well as the mean and standard
deviation (SD). The differences between means were
calculated with a one-way ANOVA. The multivariate
analysis was performed by logistic regression. All the
calculations were carried out using the statistical software
SPSS (version 17.0, SPSS Inc. Chicago, IL, USA).
Results
Patient demographics and characteristics
At the time of the data audit, 61 patients from 11 Polish
hematology centers were enrolled in the CUP, and this
report comprises the outcomes of all of these patients. One
center contributed 17 patients, one 10 patients, one 6
patients, two centers 5 patients each, three centers 4 patients
each, and three enrolled 2 patients each. The characteristics
of the patients are shown in Table 1. The majority of the
patients were male (55.7%), and the median age was
51 years, ranging from 19 to 71 years. The median body
weight was 77 kg, but it ranged between 49 and 114 kg.
Twenty-three patients (37.7%) suffered from MM, 18
(29.5%) from HL, and 20 (32.8%) from NHL. Among the
last group, eight had a diagnosis of diffuse large B-cell
lymphoma, four mantle-cell lymphoma, three marginal
Table 1 Characteristics of patients
Variable All MM NHL HL
N=61 N=23 (37.7%) N=20 (32.8%) N=18 (29.5%)
Gender
Female (%) 44.3 56.5 35.0 38.9
Male (%) 55.7 43.5 65.0 61.1
Age (years) (median, range) 51 (19–71) 60 (48–71) 51 (21–64) 26.5 (19–57)
Body weight (kg); N 55 22 18 18
Median (range) 77 (49–114) 74.5 (53–113) 78.5 (60–107) 75.5 (49–114)
Radiotherapy (%) 24.6 26.1 25.0 22.2
Previous autoSCT (%) 18.0 34.8 5.0 11.1
No. of previous chemotherapy courses (median, range) 12 (4–37) 11 (4–37) 12 (5–17) 12 (6–18)
No. of previous chemotherapy regimens (median, range) 3 (2–7) 3 (2–7) 3 (2–6) 3 (2–5)
No. of previous mobilization attempts (median, range) 1 (0–4) 1 (0–2) 1 (0–3) 1 (0–4)
Disease status
CR (%) 37.7 17.4 45.0 55.6
PR (%) 47.5 73.9 35.0 27.8
SD (%) 9.8 0 15.0 16.7
PD (%) 4.9 8.7 5.0 0
BM infiltration
0%; N (%) 34 (68.0) 6 (30.0) 13 (86.7) 15 (100.0)
<20%; N (%) 11 (22.0) 10 (50.0) 1 (6.7) 0
20–49%; N (%) 4 (8.0) 3 (15.0) 1 (6.7) 0
50–89%; N (%) 1 (2.0) 1 (5) 0 0
90–100%; N (%) 0 0 0 0
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lymphocytic lymphoma, one anaplastic lymphoma, one
small lymphocytic lymphoma, and one Waldenström’s
macroglobulinemia. All the patients had been treated
previously for their primary disease. Fifteen (24.6%) of
the patients had been treated with radiotherapy, and 11
(18%) had undergone autoSCT previously. Among the
latter group, a single patient underwent double autoSCT.
All the patients received chemotherapy before the attempt
at mobilization. They were treated with a median of 12
chemotherapy courses, ranging between four and 37, which
corresponded to a median of three (two to seven)
chemotherapy regimens. Fifty-one patients (83.6%) had
undergone at least one previous failed attempt at stem cell
mobilization, whereas 10 patients (16.4%) were predicted
to be poor mobilizers. The median number of previous
attempts at stem cell collection was one and ranged
between zero and four. Among a total of 69 failed stem
cell collection regimens, the majority (89.86%) involved
chemotherapy plus G-CSF; G-CSF alone was used in four
patients and BM aspiration in three patients (5.79% and
4.35%, respectively) (Table 2). Among the patients treated
with plerixafor and G-CSF without chemotherapy, G-CSF
(10 μg/kg) was administered as a single daily dose to 32
patients, whereas in 19 patients the dose was split into two
daily injections (2×5 μg/kg). Twenty-three patients
(37.7%) were in CR at the time of mobilization, 29
(47.5%) in PR, six (9.8%) had StD, and three (4.9%) had
PD. Among the patients with known data, 34 did not have
BM infiltration in the last trephine biopsy before mobiliza-
tion, 11 had infiltration below 20%, four between 20 and
49%, and one above 50%.
When analyzed in subgroups on the basis of their
diagnosis (Table 1), the majority of patients with NHL
and HL were male (65% and 61%, respectively), whereas
the majority of patients with MM (56.5%) were female. The
median age of the patients with HL was the lowest, at
26 years, whereas the median age of patients with NHL and
MM was 51 and 60 years, respectively. Almost 35% of the
patients with MM had undergone autoSCT previously, in
contrast to 5% of the patients with NHL and 11% of the
patients with HL. The MM group was also characterized by
the lowest proportion of patients in CR and without BM
infiltration compared with the patients with NHL and HL
(17.4% vs. 45% vs. 55.6% and 30% vs. 86.7% vs. 100%,
respectively). The groups did not differ markedly with
respect to median body weight, frequency of previous
radiotherapy treatment, number of previous chemotherapy
courses and regimens, or previous mobilization attempts.
The specific entry requirements of the CUP were waived
for some patients with accompanying disorders who, in the
opinion of the physician, would benefit from enrollment.
Three patients (5.4%) suffered from renal insufficiency as
defined by each center; the overall median serum creatinine
level was 0.8 mg/dL (range, 0.58–1.3). Three patients
suffered from liver insufficiency. The median ALT level
was 21 U/L (range, 3–126) and median total bilirubin was
0.52 mg/dL (range, 0.27–1.27). Another three patients
suffered from heart failure, and the median ejection fraction
was 65% (range, 40–76%). In five out of 42 patients with
known data (11.9%), the WBC count was <2.5 G/L, but the
median PB WBC count in all patients was 4.4 G/L (range,
1.63–19.3). A Plt count below 85 G/L was observed in
three patients (7.1% of patients with known data), and the
overall median Plt count was 149 G/L (range, 61–442). The
median Hb level was 11.8 mg/dL (range, 8.2–15.9).
In 10 patients, plerixafor was used in addition to a
chemotherapy-based mobilization regimen. These patients
were predicted to be poor mobilizers on the basis of low
CD34+ cell numbers in the PB at optimal time points
following chemotherapy plus G-CSF. In four patients, the
chemotherapy regimen was ifosfamide, carboplatin, and
etoposide (ICE); in two high-dose cyclophosphamide
(HD-Cy); and single patients underwent mobilization after
cyclophosphamide, etoposide, and dexamethasone (CED);
bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, and prednisone (BEACOPP);
dose-escalated BEACOPP; and rituximab, methotrexate,
cyclophosphamide, doxorubicin, vincristine, and prednisone
(R-Mtx-MegaCHOP), respectively. The timing of the
administration of plerixafor in this setting depended on
individual decisions made by the investigators.
Table 2 Chemotherapy regimens used for failed stem cell mobiliza-
tions preceding mobilization with plerixafor and G-CSF
Chemotherapy regimen Number of mobilization attempts
HD-Cy 25
ICE 7
IVE 7
ESHAP 4
BEACOPP escalated 3
CED 2
Cy + etoposide 3
Dexa-BEAM 2
DHAP 1
R-ICE 1
HD-etoposide 2
BEACOPP 1
HyperCVAD 1
HAD-R 1
MA 1
The abbreviations denote commonly used chemotherapy courses (look
at http://chemoregimen.com/)
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PB CD34+ cell counts after the first administration of
plerixafor (before the first planned apheresis) were avail-
able for 52 patients. Data on the PB CD34+ cell count after
the second and third injections of plerixafor were available
for 32 and 14 patients, respectively (Fig. 1, Table 3). The
median number of circulating CD34+ cells after the first
administration of plerixafor was 22/μL, ranging between
0 and 121/μL. It exceeded the threshold number of 20
CD34+ cells/μL in 31 patients (58.5%). On days 2 and 3,
the median PB CD34+ count was 16 cells/μL (range, 0.6–
98) and 11 cells/μL (range, 3–50), respectively. However,
when analyzed in patients who had number of PB CD34+
cells assessed both on days 1 and 2 (N=32), the median PB
CD34+ cell counts on these days did not differ (median of
16 CD34+ cells/μL and range 0–121 CD34+ cells/μLo n
day 1, and median of 16 CD34+ cells/μL and range of 0.6–
98 CD34+ cells/μL on day 2).
The mobilization regimen was associated with high
leukocytosis on day 1 (median WBC 36.8 G/L, range
1.1–92.1). Aphereses were performed in all but nine
patients (i.e., in 85.2%). The median number of days of
apheresis was 2 days, and it ranged between 0 and 4 days.
The median total number of CD34+ cells collected was
2.67×10
6/kg b.w., and ranged between 0 and 8.0×10
6/kg b.
w. (Table 3). The procedure was associated with a high
number of NCs in the stem cell product, and the median
total count of NCs was 9.3×10
8/kg b.w. (range, 0–40.4).
The minimum target of ≥2.0×10
6 CD34+ cells/kg b.w. was
collected in 40 patients (65.6%). Among these patients, the
median number of days of apheresis needed to exceed the
level of ≥2.0×10
6 CD34+ cells/kg b.w. was 2 days and
ranged between 1 and 3 days. During the first, second, and
third days of apheresis, a median of 1.19, 1.13, and 0.8×
10
6 CD34+ cells/μL was collected, respectively (Fig. 2). In
those patients, in whom aphereses were performed both
after first and second plerixafor administration (N=41), the
yield of CD34+ cells did not differ between collections. In
the first apheresis, the median of 1.14×10
6 CD34+ cells/kg
b.w. (range, 0.01–2.7) was collected, while the median
yield of second apheresis was 1.19×10
6 CD34+ cells/kg b.w.
(range, 0.02–3.53).
When the patients were analyzed in subsets on the basis
of their diagnosis, we observed the lowest WBC count after
the first injection of plerixafor in patients with NHL (mean
28.2 G/L, p<0.05), as well as the lowest PB CD34+ cell
count (mean 19.8 CD34+ cells/μL) (Table 4). The PB
CD34+ cell count exceeded 20 cells/μL in only 36.8% of
patients with NHL, compared with 84.2% of patients with
MM and 53.3% of those with HL. Consequently, the lowest
mean total CD34+ cell dose was collected from patients
with NHL (1.69×10
6 CD34+ cells/kg b.w.), compared with
2.99×10
6 CD34+ cells/kg b.w. from patients with MM
and 2.98×10
6 CD34+ cells/kg b.w. from patients with HL
(p<0.05).
Factors affecting the CD34+ cell yield
Factors that could potentially influence the ability to collect
at least 2.0×10
6 CD34+ cells/kg b.w. were assessed using
univariate analysis (Table 5). The diagnosis of NHL was
associated with the lowest proportion of patients who
achieved the collection goal (40%), as compared with
patients with MM (78.3%) or HL (77.8%) (p<0.05).
Similarly, ≥2.0×10
6 CD34+ cells/kg b.w were collected in
only 40% of patients treated with radiotherapy, as compared
with 73.9% of those who did not receive such treatment
(p<0.05). Importantly, mobilization was successful in all
the patients who had been treated with plerixafor in first-
line mobilizations, compared with successful mobilization
in 58.8% of the remaining patients (p<0.05). Mobilization
also tended to be more successful in female as compared
with male patients (77.8% vs. 55.9%), in patients ≤40 vs.
>40 years of age (80% vs. 58.5%), those treated with ≤12
vs. >12 courses of chemotherapy (73.5% vs. 55.6%), and
those who received ≤3 vs. >3 chemotherapy regimens
(74.4% vs. 50%); however, these differences were not
significant. Importantly, mobilization was successful in
only one out of seven patients (14.3%) who were treated
with purine analogs, as compared with 72.2% of patients
who did not receive these drugs (p<0.01). Similarly, the
required number of CD34+ cells was collected in only
31.3% of patients treated with rituximab (anti-CD20), in
contrast to 77.3% of the remaining patients (p=0.001).
Given that the characteristics of the patients and previous
therapies differed considerably between cases of MM,
NHL, and HL, a similar analysis was performed in the
subsets of patients based on the diagnosis (Table 5). This
analysis confirmed the above trends; however, the low
number of patients in each subset contributed to the low
Fig. 1 Circulating peripheral blood CD34+ cells/μLa f t e re a c h
administration of plerixafor. Error bars represent the 10–90% range,
boxes represent the 25–75% range, x represents the median
562 Ann Hematol (2011) 90:557–568power in the analysis. Multivariate analysis of the diagnosis
and factors that were thought to be independent from
diagnosis (gender, number of chemotherapy courses, and
radiotherapy) confirmed the significance of the diagnosis of
NHL (p<0.05; odds ratio, 6.73) and previous radiotherapy
(p<0.05; odds ratio, 5.49) as factors that contributed to an
inferior outcome of stem cell collection (Table 6).
Assessment of the quantity of plerixafor used
A median of two injections of plerixafor (range, one to
four) was administered in 55 evaluable patients (Table 3).
On the basis of the patient’s body weights, this translated
into a median of 42.5 mg of drug used per patient (range,
12.7–102.7 mg), with a median single dose of 18.2 mg
(range, 11.7–28.8). Taking into account the fact that a
single ampoule contains 24.0 mg of the drug, the median
number of ampoules used was 1.8, ranging between 0.5
and 4.3.
Transplantation and engraftment
Up to the last follow-up examination, 34/61 patients
(55.7%) who had participated in the CUP program had
proceeded to autoSCT. Among the 40 patients from whom
≥2.0×10
6 CD34+ cells/kg b.w. were collected, 30 had
already undergone stem cell transplantation (SCT; 75.0%),
in contrast to the four of 21 patients (19.0%) whose stem
cell collection had failed. The conditioning regimens
included carmustine, etoposide, cytarabine, and melphalan
(BEAM) in 14 patients; melphalan 200 mg/m
2 (MEL200)
in 13 patients; melphalan 140 mg/m
2 (MEL140) in two
patients; and cyclophosphamide, etoposide, and carmustine
(CBV), cyclophosphamide and total body irradiation
(CyTBI), and BEAM plus dexamethasone (DexaBEAM)
in one patient each. Among the 34 patients with known
data, in 25 cases (73.5%), the transplanted stem cell product
consisted solely of cells mobilized after the plerixafor-
containing regimen. In nine patients (26.5%), the trans-
planted stem cell product was composed of cells mobilized
after the plerixafor-containing regimen mixed with cells
Fig. 2 CD34+ cell yields by day of apheresis. Error bars represent
the 10–90% range, boxes represent the 25–75% range, x represents the
median
Table 3 Outcomes of stem cell mobilization, collection, and transplantation
Outcome N (number of participants) Median (range)
CD34+ cells/μL after 1st dose of plerixafor 52 22 (0–121)
CD34+ cells/μL after 2nd dose of plerixafor 32 16 (0.6–98)
CD34+ cells/μL after 3rd dose of plerixafor 14 11 (3–50)
WBC (G/L) after 1st application of plerixafor 54 36.8 (1.1–92.1)
Number of days of apheresis 61 2 (0–4)
Day of apheresis when ≥2.0×10
6/CD34+ cells/kg was reached 37 2 (1–3)
Total No. of CD34+ cells collected (×10
6/kg b.w.) 61 2.67 (0–8.0)
Total No. of NCs collected (×10
8/kg b.w.) 57 9.3 (0–40.4)
Volume (mL) of frozen stem cell product 46 652 (169–2,300)
No. of plerixafor injections 55 2 (1–4)
Plerixafor single dose (mg) per patient 58 18.2 (11.7–28.8)
Plerixafor total dose (mg) per patient 55 42.5 (12.7–102.7)
Plerixafor ampoules per patient 52 1.8 (0.5–4.3)
Days to neutrophil engraftment 33 12 (8–20)
Days to platelet engraftment 33 14 (7–30)
N (number of participants) Proportion (%)
Patients with ≥20 CD34+ cells/μL after 1st dose of plerixafor 31 58.5
Patients yielding ≥2.0×10
6/CD34+ cells/kg b.w. 40 65.6
Patients yielding 1.0–2.0×10
6/CD34+ cells/kg b.w. 3 4.9
Patients yielding <1.0×10
6/CD34+ cells/kg b.w. 18 29.5
Ann Hematol (2011) 90:557–568 563obtained from previous or later mobilization procedures.
The median dose of CD34+ cells transplanted was 2.8×
10
6/kg b.w. and ranged between 0.94 and 5.4. In all
patients, engraftment was achieved with a median time to
neutrophil recovery (>0.5 G/L) of 12 days (range, 8–
20 days) and a median time to platelet recovery (>20 G/L)
of 14 days (range, 7–30 days) (Table 3). On the basis of the
reports of 28 patients, no cases of late graft failure were
observed within the period of the audit. The median period
from autoSCT to the last report was 15.2 weeks and ranged
between 0.3 and 51 weeks. In the group of 31 patients with
known data, two patients (6.45%) experienced continuous
progression since autoSCT, and another three patients
relapsed after 11, 13, and 18 weeks, respectively.
Discussion
Plerixafor (AMD3100, Mozobil) is a new drug in the field
of HSC transplantation and is designed to be used in
combination with G-CSF for stem cell mobilization in
patients with myeloma or lymphoma. As shown recently
in two multicenter randomized double-blind placebo-
controlled studies, the effect of plerixafor and G-CSF is
superior to that of G-CSF and placebo [10, 11]. Before
the results of those studies were published, plerixafor had
already been made available to American and European
transplant centers free of charge within the manufacturer-
funded CUP. This allowed physicians to use plerixafor in
everyday clinical situations without the strict limitations of
clinical trials. The first study conducted in the United States
within the CUP revealed that the minimum requirement of
2.0×10
6 CD34+ cells/kg b.w. was collected from 66% of
patients [14]. Since that time, a number of authors have
reported an overall success rate of mobilization of 70–100%
after the administration of plerixafor in combination with
G-CSF [15–24]. However, the characteristics of the patients,
local circumstances, and the number of doses of plerixafor
available differed considerably between the studies and may
have affected the outcome. Moreover, these studies involved
small groups of patients, with a maximum number of 49
patients reported by Stiff et al. [17]. The uncertainty
regarding how these results translate into clinical practice
stimulated us to evaluate retrospectively the results of the
CUP in Poland.
We managed to collect data regarding plerixafor-based
stem cell mobilizations in 61 patients, which is the largest
group following the report by Calandra et al. [14]. The
primary goal of the study was to investigate the efficiency
of plerixafor in stem cell mobilization, expressed as the
number of circulating CD34+ cells and the total number of
CD34+ cells collected during aphereses. In our group of
patients, a median of 22 circulating CD34+ cells/μL was
observed after the first injection of plerixafor. Calandra
et al.[14] did not report the relevant data for comparison,
but in the study by Tricot et al. [15] the median PB CD34+
Outcomes Median (range) Mean (±SD) p
WBC after 1st application of plerixafor (G/L)
MM (N=19) 42 (9.3–88.1) 42.2 (±20.0) <0.05
NHL (N=18) 22.3 (1.1–72.5) 28.2 (±19.9)
HL (N=17) 38.8 (14.1–92.1) 44.0 (±21.2)
PB CD34+ cells/μL after 1st dose of plerixafor
MM (N=19) 30 (11–74) 33.7 (±17.2) N.S.
NHL (N=19) 13 (0–65) 19.8 (±22.4)
HL (N=14) 22 (11–121) 33.9 (±29.7)
Total No. of CD34+ cells collected (×10
6/kg b.w.)
MM (N=23) 2.8 (0.6–5.5) 2.99 (±1.5) <0.05
NHL (N=20) 0.89 (0–6.5) 1.69 (±1.9)
HL (N=18) 2.8 (0–8.0) 2.98 (±2.0)
N (number of participants) Proportion (%)
Patients with ≥ 20 PB CD34+ cells/μL after 1st dose of plerixafor
MM (N=19) 16 84.2 <0.01
NHL (N=19) 7 36.8
HL (N=14) 8 53.3
Patients yielding≥2.0×10
6/CD34+ cells/kg b.w.
MM (N=23) 18 78.3 <0.05
NHL (N=20) 8 40.0
HL (N=18) 14 77.8
Table 4 Major outcomes of
stem cell mobilization and
collection in patient subsets
according to diagnosis
N.S. not significant
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Ann Hematol (2011) 90:557–568 565cell count was only 6 cells/μL. In contrast, Stiff et al. and
Fruehauf et al. reported a much higher median number
of CD34+ cells: 56 cells/μL and 69 cells/μL, respectively
[17, 18]. On the basis of the above-mentioned reports, it
seems that this parameter depends largely on patient
selection. The study of Tricot et al., which was similar to
our study, investigated patients in whom previous mobili-
zation attempts had failed. On the other hand, Stiff et al.
and Fruehauf et al. presented data on patients in whom
plerixafor was used as a first-line treatment. In the study of
Fruehauf et al., a median of 22 CD34+ cells/μL was already
observed after treatment with G-CSF alone, before the
administration of plerixafor, and this value was identical to
the median obtained in our study after injection of
plerixafor [18]. Furthermore, we noted that the median
number of PB CD34+ cells decreased after each adminis-
tration of plerixafor, and a similar observation was made by
Fowler et al. [16]. Similarly, the median CD34+ cell yield
obtained in consecutive aphereses seemed to be decreasing.
This phenomenon could indicate tachyphylaxis, i.e., a
decrease in the response to plerixafor after repeated drug
doses over a relatively short period of time. However, the
results of these analyses seem to be biased by clinical
practice of CD34+ cell enumeration and cell collection.
Namely, in patients with satisfactory counts of circulating
CD34+ cells after the first administration of plerixafor,
apheresis was usually performed after the second and third
injections of plerixafor without further assessment of
CD34+ cells. Therefore, the median number of CD34+
cells/μL after the second and third injections of plerixafor
might reflect primarily the PB CD34+ cell counts in
patients who did not achieve satisfactory results on the
first day, and therefore were lower. Similarly, in good
mobilizers, who collected abundant number of CD34+ cells
in the initial apheresis, the consecutive aphereses were not
done, and thus these patients did not contribute to the
analysis. The further results of our study seem to confirm
these theses. Patients who had PB CD34+ cell measure-
ments done both on days 1 and 2 mobilized similar number
of CD34+ cells after first and second injection of plerixafor.
Similarly, in those patients who underwent two aphereses,
the CD34+ cell yield was similar in each of the collections.
Based on above observations, the evidence for tachyphy-
laxis reaction in response to plerixafor could not be
confirmed and needs to be further investigated in a larger
cohort of patients.
In our study, ≥2.0×10
6 CD34+ cells/kg b.w., which is
the minimum number required for SCT, were collected
from 65.6% of patients. The success rate was similar to that
reported by Calandra et al. [14] and lower than in the
majority of the remaining reports. The median cell yield of
2.67×10
6 CD34+ cells/kg b.w. was lower than that in most
studies. Differences in the procedures of cell collection
could contribute to this finding. In our study, the median
number of days of apheresis was 2 days, extending up to
4 days. In contrast, in the study by Calandra et al., the
median number of days of apheresis was 3 days, ranging up
to 7 days [14]. Tricot et al., who reported a very low
median number of PB CD34+ cells, as discussed above,
achieved a higher rate of success of collection (75%) [15].
However, the majority of their patients underwent seven
aphereses on consecutive days in order to achieve the goal
of mobilization. Therefore, increasing the number of days
of apheresis (and the number of injections of plerixafor)
might increase both the total CD34+ cell yield and the
success rate. Under normal clinical circumstances, the high
cost of plerixafor and limited access to apheresis resources
will certainly limit the number of days of apheresis to a
minimum. Therefore, it is likely that our data give a better
representation of the outcome of plerixafor-based mobili-
zation than those obtained in other studies.
A diagnosis of NHL and previous radiation treatment
were shown to be predictive factors for mobilization failure;
they had been shown previously to have this effect in
standard mobilizations [9, 25]. In addition, the observed
trend towards inferior plerixafor-based mobilization in
patients who had received multiple courses and regimens
of chemotherapy and in patients treated with purine analogs
has been documented previously in the context of standard
approaches to mobilization [25, 26]. To our knowledge, we
are the first to identify treatment with rituximab as a factor
that affects stem cell mobilization adversely. This could be
related to the role of B lymphocytes, which are the target of
rituximab, in complement activation during stem cell
mobilization [27]. Given that the heterogeneity of the
patient group analyzed might affect the outcome of both
univariate and multivariate analyses, we performed the
analysis in subgroups that were separated on the basis of
diagnosis. Unfortunately, sufficient data for statistical
analysis could not be obtained from each of the diagnostic
groups, owing to low patient numbers. Analysis of a larger
cohort of patients is warranted.
Table 6 Multivariate analysis of factors affecting the probability of
collection of <2.0×10
6 CD34+ cells/kg b.w.
Variable p Odds ratio
Diagnosis
MM 0.017 –
HL 0.902 0.9
NHL 0.013 6.727
Male gender 0.484 1.636
No. of chemotherapy courses >12 0.083 0.316
Radiotherapy 0.029 5.499
566 Ann Hematol (2011) 90:557–568We have shown previously, on the basis of experience in
a single center, that mobilization with plerixafor in
combination with G-CSF is associated frequently with very
high PB leukocytosis [24], and this was also confirmed in
the current study. High leukocytosis has been shown
previously to be related to an inferior outcome of stem
cell collection [28]. This may potentially affect cell
collections in European apheresis centers, which tend to
use chemotherapy-based stem cell mobilization. In such
cases, leukocytosis is usually much lower. High leukocy-
tosis requires adaptation of the apheresis procedure to
increase the separation of cell fractions, to maximize the
use of CD34+ cells mobilized to the PB, and to avoid an
abundance of NCs in the apheresis products. We have
shown that the number of NCs in stem cell products is
high, and in general, this increases the volume of frozen
stem cell preparations.
Importantly, mobilization with plerixafor allowed pro-
gression to SCT in 55.7% of patients in whom previous
mobilization attempts had failed. However, owing to the
fact that the period from mobilization to the last follow-up
was short, a number of patients from whom the required
number of CD34+ cells had been collected had not received
transplants at the time of the study. Moreover, some
patients from whom fewer than 2.0×10
6 CD34+ cells/kg
were collected after mobilization with plerixafor also
benefited from the procedure. One of these patients has
been transplanted successfully with 1.94×10
6 CD34+ cells/
kg b.w, whereas several of them have received stem cell
products pooled from several mobilizations, which were
sufficient to provide the adequate number of CD34+ cells.
The potential risks of autoSCT after myeloablative
conditioning are graft loss and delayed recovery of platelets
and neutrophils. As shown in the current report, the cells
mobilized with plerixafor engrafted in all cases, and a
satisfactory time to platelet and neutrophil regeneration was
observed, which was similar to or shorter than those
reported by others [19–24]. However, one could argue that
plerixafor mobilizes mostly the stem cell fractions that are
responsible for short-term reconstitution of hematopoiesis,
which could result in late graft failure. We did not observe
such an event within the study period. There are several
limitations of the study. The standard of care of the patients
was not monitored, and the sites were not trained in the
conduct of the CUP. In contrast to centers monitored by
Calandra et al. [14], the clinicians had no prior experience
with the drug and had to learn how to use it. However,
paradoxically, these limitations might contribute to the
value of the current study because it represents a real
clinical situation, which is frequently far from that
described in prospective clinical studies. The current report
shows the benefit of stem cell mobilization with plerixafor
in 65.6% of heavily pretreated patients who were poor or
predicted to be poor mobilizers. Moreover, our data indicate
a worse outcome of mobilization with plerixafor and
G-CSF in patients suffering from NHL, as well as in
patients who had been treated previously with radiotherapy,
than in other groups.
Plerixafor was already approved in United States (2008)
and in Europe (2009) for HSC mobilization in myeloma
and lymphoma patients. Unfortunately, the cost of treatment
with plerixafor is high, and despite the high efficiency of
the drug, it is not reimbursed by health care providers in
Poland and in most of European countries. Our report may
help the physicians to optimize the use of plerixafor in
patients with different pre-mobilization features.
Acknowledgements We would like to acknowledge sincerely all the
physicians and laboratory staff taking part in the plerixafor CUP in
Poland. We would also like to thank the drug manufacturer, Genzyme
Corp., for providing plerixafor free of charge. We would also like to
thank all the physicians and laboratory staff not mentioned as
coauthors, who contributed to stem cell mobilization and to data
collection.
Conflict of interest G.W.B. declares honoraria from Genzyme and
reimbursements for participation in scientific conferences.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Harousseau JL (2009) Hematopoietic stem cell transplantation in
multiple myeloma. J Natl Compr Canc Netw 7(9):961–970
2. Moskowitz AJ, Moskowitz CH (2009) Controversies in the
treatment of lymphoma with autologous transplantation. Oncologist
14(9):921–929. doi:10.1634/theoncologist.2009-0162
3. Gratwohl A, Baldomero H, Schmid O, Horisberger B, Bargetzi M,
Urbano-Ispizua A (2005) Change in stem cell source for
hematopoietic stem cell transplantation (hsct) in europe: a report
of the ebmt activity survey 2003. Bone Marrow Transplant 36
(7):575–590. doi:10.1038/sj.bmt.1705104
4. Bender JG, To LB, Williams S, Schwartzberg LS (1992) Defining
a therapeutic dose of peripheral blood stem cells. J Hematother 1
(4):329–341
5. Montgomery M, Cottler-Fox M (2007) Mobilization and collec-
tion of autologous hematopoietic progenitor/stem cells. Clin Adv
Hematol Oncol 5(2):127–136
6. Bensinger W, DiPersio JF, McCarty JM (2009) Improving stem
cell mobilization strategies: future directions. Bone Marrow
Transplant 43(3):181–195. doi:10.1038/bmt.2008.410
7. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L,
Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ (2004) Cxcr4-
sdf-1 signalling, locomotion, chemotaxis and adhesion. J Mol
Histol 35(3):233–245
8. Villalon L, Odriozola J, Larana JG, Zamora C, Perez de Oteyza J,
Jodra MH, Lopez J, Herrera P, Roldan E, Ramos ML, Ramos P,
Navarro JL (2000) Autologous peripheral blood progenitor cell
Ann Hematol (2011) 90:557–568 567transplantation with <2×10(6) cd34(+)/kg: an analysis of variables
concerning mobilisation and engraftment. Hematol J 1(6):374–381.
doi:10.1038/sj/thj/6200057
9. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF,
Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek
DS, Smith AL, DiPersio JF (2008) Impact of mobilization and
remobilization strategies on achieving sufficient stem cell yields
for autologous transplantation. Biol Blood Marrow Transplant 14
(9):1045–1056. doi:10.1016/j.bbmt.2008.07.004
10. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ,
Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M,
Cooper D, Bridger G, Calandra G (2009) Plerixafor and g-csf
versus placebo and g-csf to mobilize hematopoietic stem cells for
autologous stem cell transplantation in patients with multiple
myeloma. Blood 113(23):5720–5726. doi:10.1182/blood-2008-
08-174946
11. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT,
Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G
(2009) Phase iii prospective randomized double-blind placebo-
controlled trial of plerixafor plus granulocyte colony-stimulating
factor compared with placebo plus granulocyte colony-stimulating
factor for autologous stem-cell mobilization and transplantation
for patients with non-hodgkin’s lymphoma. J Clin Oncol 27
(28):4767–4773. doi:10.1200/JCO.2008.20.7209
12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L,
Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen
ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K,
Vose JM, Connors JM, Federico M, Diehl V (2007) Revised
response criteria for malignant lymphoma. J Clin Oncol 25
(5):579–586. doi:10.1200/JCO.2006.09.2403
13. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B,
Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P,
Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro
M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian
R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu
K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform
response criteria for multiple myeloma. Leukemia 20(9):1467–
1473. doi:10.1038/sj.leu.2404284
14. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel
K, Grove B, Dye A, Bridger G (2008) Amd3100 plus g-csf can
successfully mobilize cd34+ cells from non-hodgkin’s lymphoma,
hodgkin’s disease and multiple myeloma patients previously
failing mobilization with chemotherapy and/or cytokine treatment:
compassionate use data. Bone Marrow Transplant 41(4):331–338.
doi:10.1038/sj.bmt.1705908
15. Tricot G, Cottler-Fox MH, Calandra G (2010) Safety and efficacy
assessment of plerixafor in patients with multiple myeloma proven
or predicted to be poor mobilizers, including assessment of tumor
cell mobilization. Bone Marrow Transplant 45(1):63–68.
doi:10.1038/bmt.2009.130
16. Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L,
Lanier K, Nelson V, Kovacsovics T, Leis J, Calandra G, Maziarz
RT (2009) Rescue from failed growth factor and/or chemotherapy
hsc mobilization with g-csf and plerixafor (amd3100): an
institutional experience. Bone Marrow Transplant 43(12):909–
917. doi:10.1038/bmt.2008.409
17. Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf
D, Territo M, Badel K, Calandra G (2009) Treatment with
plerixafor in non-hodgkin’s lymphoma and multiple myeloma
patients to increase the number of peripheral blood stem cells
when given a mobilizing regimen of g-csf: implications for the
heavily pretreated patient. Biol Blood Marrow Transplant 15
(2):249–256. doi:10.1016/j.bbmt.2008.11.028
18. Fruehauf S, Ehninger G, Hubel K, Topaly J, Goldschmidt H, Ho
AD, Muller S, Moos M, Badel K, Calandra G (2010) Mobilization
of peripheral blood stem cells for autologous transplant in non-
hodgkin’s lymphoma and multiple myeloma patients by plerixafor
and g-csf and detection of tumor cell mobilization by pcr in
multiple myeloma patients. Bone Marrow Transplant 45(2):269–
275. doi:10.1038/bmt.2009.142
19. Hubel K, Fresen M, Lange F, Salwender H, Basara N, Bogner C,
Galm O, Hartwig R, Dressler S, Ebinger M, Frickhofen N,
Hertenstein B, Kiehl M, Liebler S, Von Lilienfeld-Toal M,
Weidmann E, Weigelt C, Kroner N (2010) Plerixafor for stem
cell mobilization in poor mobilizers: results from the german
compassionate use programme. Bone Marrow Transplant 45
(Supplement 2):S316
20. Worel N, Rosskopf K, Nachbaur D, Kasparu H, Russ G,
Namberger K, Leitner G, Kalhs P, Schogl E, Witt V, Greinix H,
Keil F, Linkesch W (2010) Plerixafor plus g-csf can success-
fully mobilize cd34+ cells from patients who have previously
failed chemotherapy and/or cytokine mobilization: the compas-
sionate use experience in austria. Bone Marrow Transplant 45
(Supplement 2):S318
21. Mohty M, Lefrere F, Caillot D, Azar N, Miclea JM, Broussais F,
Marolleau JP, Attal M, Milpied N, Gisselbracht C, Moreau P,
Chabannon C (2010) Plerixafor plus g-csf can mobilize autolo-
gous haematopoietic stem cells from heavily pre-treated patients
failing previous mobilization attempts: analysis of the french
compassionate use programme. Bone Marrow Transplant 45
(Supplement 2):S319
22. Koristek Z, Folber F, Lysak D, Pohlreich D, Lanska M,
Rusinakova Z, Papajik T, Kepak T, Novak J, Mayer J, Erba J
(2010) The use of plerixafor in czech transplant centers. Bone
Marrow Transplant 45(Supplement 2):S320
23. Jaksic O, Basic-Kinda S, Maricic I, Bojanic I, Nemet B, Pejsa V,
Labar B (2010) Effective stem cell mobilization with plerixafor +
g-csf followed by large-volume leukapheresis in poor mobilizers:
the experience of the croatian cooperative group for hematologic
diseases(krohem).BoneMarrowTransplant45(Supplement2):S321
24. Basak GW, Urbanowska E, Witkowska M, Zdunczyk D,
Waszczuk-Gajda A, Skwierawska K, Drozd J, Skibinska M,
Glazer M, Madry K, Halaburda K, Torosian T, Krol M, Wiktor-
Jedrzejczak W (2010) Stem cell mobilization with plerixafor in
poorly mobilizing myeloma and lymphoma patients—a single
centre experience and strategies. Bone Marrow Transplantation 45
(Supplement 2):S320
25. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J,
Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C et al
(1995) Factors that influence collection and engraftment of
autologous peripheral-blood stem cells. J Clin Oncol 13
(10):2547–2555
26. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A,
TremisiP,ThieblemontC,DurandB,Neidhardt-BerardEM,Samaha
H, Rigal D, Coiffier B (1998) Factors associated with successful
mobilization of peripheral blood progenitor cells in 200 patients with
lymphoid malignancies. Br J Haematol 103(1):235–242
27. Reca R, Cramer D, Yan J, Laughlin MJ, Janowska-Wieczorek A,
Ratajczak J, Ratajczak MZ (2007) A novel role of complement in
mobilization: immunodeficient mice are poor granulocyte-colony
stimulating factor mobilizers because they lack complement-
activating immunoglobulins. Stem Cells 25(12):3093–3100.
doi:10.1634/stemcells.2007-0525
28. PA BEA, Winters JL (2003) Effects of high whole blood flow
rates and high peripheral blood cell counts on cd34+ cell yield and
cross-cellular contamination. Cytotherapy 5:446
568 Ann Hematol (2011) 90:557–568